Short-term influence of Immufen™ on mild allergic rhinitis: a randomized, double-blind, placebo-controlled study – PubMed Black Hawk Supplements

Introduction: Allergic rhinitis (AR) is an IgE-mediated reaction to inhaled allergens, and is a prominent health concern affecting approximately 400 million people worldwide. A comprehensive understanding of AR’s pathophysiology is imperative for developing novel therapies, especially considering its frequent co-morbidity with asthma and conjunctivitis. The escalating prevalence of AR is correlated with increased urbanization and environmental pollutants, recognized as prominent contributing factors. Dysregulation in immune networks, Th1/Th2 cytokine imbalance, activation of mast cells and eosinophils are implicated in AR progression. Classic AR symptoms include nasal congestion, nasal itching, rhinorrhea, and sneezing which significantly impact the quality of life, social interactions, and workplace productivity.

Methods: This randomized, double-blind, placebo-controlled, three-arm, three-sequence study was aimed to assess the efficacy of supplementation of a co-delivery form of turmeric extract with ashwagandha extract (CQAB) in comparison with a bioavailable curcumin (CGM) and placebo in alleviating AR symptoms and enhancing the quality of life in individuals with mild AR. Participants received either placebo, CGM, or CQAB twice/day for 28 days, and subjective measures were recorded at the baseline and at the end of study.

Results: CQAB supplementation demonstrated a significant (P < 0.05) improvement in Total Nasal Symptom Score (TNSS) compared to placebo and CGM. Furthermore, CQAB administration resulted in enhanced sleep quality (P < 0.05) as evaluated by the BIS questionnaire, heightened energy levels, and decreased fatigue and overall mood disturbance (POMS-SF) compared to both placebo and CGM.

Conclusion: The results suggests that CQAB has the potential to be used as a dietary supplement in alleviating AR discomforts.

Clinical trial registration: https://ctri.nic.in/Clinicaltrials/login.php; Identifier CTRI/2021/01/030355.

1. 1. Bjermer L, Westman M, Holmström M, Wickman MC. The complex pathophysiology of allergic rhinitis: scientific rationale for the development of an alternative treatment option. Allergy Asthma Clin Immunol. (2019) 15(1):1–15. 10.1186/s13223-018-0314-1 – DOI – PMC – PubMed
2. 1. Husna SMN, Tan HTT, Md Shukri N, Mohd Ashari NS, Wong KK. Allergic rhinitis: a clinical and pathophysiological overview. Front Med (Lausanne). (2022) 9:1–10. 10.3389/fmed.2022.874114 – DOI – PMC – PubMed
3. 1. Ke X, Chen Z, Wang X, Kang H, Hong S. Quercetin improves the imbalance of Th1/Th2 cells and Treg/Th17 cells to attenuate allergic rhinitis. Autoimmunity. (2023) 56(1):1–9. 10.1080/08916934.2023.2189133 – DOI – PubMed
4. 1. Licari A, Manti S, Ciprandi G. What are the effects of rhinitis on patients with asthma? Expert Rev Respir Med. (2019) 13(6):503–5. 10.1080/17476348.2019.1604227 – DOI – PubMed
5. 1. Ozdoganoglu T, Songu M, Inancli HM. Quality of life in allergic rhinitis. Ther Adv Respir Dis. (2012) 6(1):25–39. 10.1177/1753465811424425 – DOI – PubMed